Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746 | 0.82 | — | — | |
| SCHEMBL5544690 | 0.82 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL7097725 | 0.82 | — | — | |
| SCHEMBL899432 | 0.79 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL319537 | 0.78 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL3210291 | 0.78 | MEN1 (0.40) | MEN1KMT2A | |
| Fluoride SCHEMBL73855 | 0.78 | MEN1 (0.40) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL1997314 | 0.78 | MEN1 (0.40) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22577541 | 0.78 | MEN1 (0.40) | MEN1KMT2A | |
| Fluoride SCHEMBL1025917 | 0.78 | MEN1 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573902-B2 | Process for the preparation of Ivacaftor and its intermediates | LAURUS LABS PRIVATE LTD. (IN) | 2017-02-21 | — | — | US | claimed |
| US-20160016909-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS LIMITED (IN) | 2016-01-21 | — | — | US | claimed |
| WO-2014125506-A2 | A PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS PRIVATE LIMITED (IN) | 2014-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016909-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | SLC10A2, SLC26A4, SLC10A1 | CYP1A2 433/4885MAPK1 2655/4885CA12 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.